SEARCH

SEARCH BY CITATION

References

  • Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC (1997) Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272, 348361.
  • Cavallucci V, D'Amelio M, Cecconi F (2012) Abeta toxicity in Alzheimer's disease. Mol. Neurobiol. 45, 366378.
  • Chen L, Cai W, Zhou R, Furuya K, Sokabe M (2010) Modulatory metaplasticity induced by pregnenolone sulfate in the rat hippocampus: a leftward shift in LTP/LTD-frequency curve. Hippocampus 20, 499512.
  • Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 7984.
  • Ge HM, Zhu CH, da Shi H, Zhang LD, Xie DQ, Yang J, Ng SW, Tan RX (2008) Hopeahainol A: an acetylcholinesterase inhibitor from Hopea hainanensis. Chemistry 14, 376381.
  • He XY, Wen GY, Merz G, Lin D, Yang YZ, Mehta P, Schulz H, Yang SY (2002) Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model. Brain Res. Mol. Brain Res. 99, 4653.
  • Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216223.
  • Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448452.
  • Marques AT, Fernandes PA, Ramos MJ (2009) ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease. Mini. Rev. Med. Chem. 9, 10021008.
  • Muirhead KE, Borger E, Aitken L, Conway SJ, Gunn-Moore FJ (2010) The consequences of mitochondrial amyloid beta-peptide in Alzheimer's disease. Biochem. J. 426, 255270.
  • Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63, 21792184.
  • Nicolaou KC, Kang Q, Wu TR, Lim CS, Chen DY (2010) Total synthesis and biological evaluation of the resveratrol-derived polyphenol natural products hopeanol and hopeahainol A. J. Am. Chem. Soc. 132, 75407548.
  • Parachikova A, Green KN, Hendrix C, Laferla FM (2010) Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS ONE 5, e14015.
  • Reinke AA, Gestwicki JE (2007) Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem. Biol. Drug Des. 70, 206215.
  • Seo JS, Lee KW, Kim TK, Baek IS, Im JY, Han PL (2011) Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease. Free Radic. Biol. Med. 50, 15261535.
  • da Shi H, Wu JH, Ge HM, Tan RX (2009) Protective effect of hopeahainol A, a novel acetylcholinesterase inhibitor, on hydrogen peroxide-induced injury in PC12 cells. Environ. Toxicol. Pharmacol. 28, 3036.
  • Smith MA, Nunomura A, Zhu X, Takeda A, Perry G (2000) Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal. 2, 413420.
  • Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, Yan SS (2005) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 19, 597598.
  • Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848858.
  • Xu Y, Zhang W, Klaus J, Young J, Koerner I, Sheldahl LC, Hurn PD, Martinez-Murillo F, Alkayed NJ (2006) Role of cocaine- and amphetamine-regulated transcript in estradiol-mediated neuroprotection. Proc. Natl Acad. Sci. USA 103, 1448914494.
  • Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689695.
  • Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 58925901.
  • Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS (2011) Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J. Neurosci. 31, 23132320.